NASDAQ:LONA Athira Pharma Q2 2026 Earnings Results & Report $3.81 +0.08 (+2.04%) As of 10:04 AM Eastern This is a fair market value price provided by Massive. Learn more. Athira Pharma missed analyst earnings expectations in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$0.80 versus the -$0.60 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 14, 2026TimeAfter Market ClosesConference Call7:00 AM ET Athira Pharma EPS ResultsActual EPS-$0.80Consensus EPS -$0.60Beat/MissMissed by -$0.20One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersAthira Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Athira Pharma Q2 2026 Earnings FAQ Did Athira Pharma beat earnings estimates for Q2 2026? Athira Pharma (NASDAQ:LONA) reported earnings of -$0.80 per share for Q2 2026, missing the consensus estimate of -$0.60. The report was announced on Friday, August 14, 2026. Athira Pharma Earnings HeadlinesLeonaBio to Participate in Cantor Global Healthcare Conference 2026September 3, 2026 | globenewswire.comSeattle-area biotech led by ex-Athira CEO Leen Kawas raises $35M for hepatitis D drugAugust 31, 2026 | msn.com$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.November 13 at 1:00 AM | Profits Run (Ad)LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | globenewswire.comLeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology's 4th Summit on Breast CancerAugust 12, 2026 | globenewswire.comLeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development SummitJune 4, 2026 | globenewswire.comSee More Athira Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Athira Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Athira Pharma and other key companies, straight to your email. Email Address About Athira PharmaAthira Pharma (NASDAQ:LONA) is a clinical-stage biotechnology company focused on developing regenerative therapies for neurodegenerative diseases. Its research has centered on treatments intended to activate the hepatocyte growth factor pathway, which may support neuronal health, repair, and regeneration. The company’s lead investigational product is fosgonimeton, formerly known as ATH-1017, an intravenous therapy developed for potential use in Alzheimer’s disease and other neurodegenerative conditions. Fosgonimeton has also been evaluated in connection with Parkinson’s disease and dementia with Lewy bodies. As an investigational medicine, it has not been approved for commercial use. Athira Pharma was founded in 2011 and has conducted its development activities primarily in the United States. Publicly available information has historically identified Leen Kawas, Ph.D., as a founder and former chief executive officer. Athira Pharma has historically been associated with the Nasdaq ticker ATHA; the ticker LONA may not correspond to the company.View Athira Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record Growth Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
